Navigation Links
Isis Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Date:10/15/2010

CARLSBAD, Calif., Oct. 15 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the 17th Annual NewsMakers in the Biotech Industry Conference on Friday, October 22, 2010 at 11:00 a.m. ET at the Millennium Broadway Hotel & Conference Center in New York.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 23 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide.  Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
2. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of Acetadote® in Australia
4. Prolong Pharmaceuticals Secures $30 Million in Funding
5. Amylin Pharmaceuticals to Webcast Third Quarter Results
6. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
7. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphine™ Data
8. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
9. Reportlinker Adds Sales Force Effectiveness in Pharmaceuticals - Cost Pressures Increase Pharmaceutical Companies Adoption of New Sales Models and Technologies
10. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
11. Jazz Pharmaceuticals Receives FDA Complete Response Letter Regarding JZP-6 for Treatment of Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... TORONTO , May 5, 2016  Replikins Ltd. today reported initial promising results ... Photo - http://photos.prnewswire.com/prnh/20160505/364345 ... ... ... Replikins analyses of all Zika specimens recorded on Pubmed. The analysis identified the highest ...
(Date:5/5/2016)... 5, 2016  Diagnostic imaging has been on ... concerns that these tests cause health care costs to spike. ... as well as the adoption of new guidelines ... peripherals that help health care providers cut costs, while helping ... imaging is a renowned authorized reseller of the medical ...
(Date:5/5/2016)... 2016 Research and ... Thalassaemia Market and Competitive Landscape Highlights - ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... Competitive Landscape Highlights - 2016, provides comprehensive ... Thalassaemia market valuations and forecast, Thalassaemia products ...
Breaking Medicine Technology:
(Date:5/6/2016)... UK (PRWEB) , ... May 06, 2016 , ... ... success in changing the way the pharmaceutical industry conducts clinical trials. This month Ibs ... most influential people in pharma, and he was honored as a Tech Disruptor by ...
(Date:5/6/2016)... ... ... variety of national pet product manufacturers, companies and brands will gather for one day only ... noon to 8 p.m. at New York City’s Roger Smith Hotel. The event is produced ... and safety pet products in today’s marketplace. , Petrend Event showcases the newest ...
(Date:5/6/2016)... , ... May 06, 2016 , ... Logically, spring weather, ... seasons, when the weather is too cold, dry or hot, water on the eye ... actually absorb moisture from the surrounding air. There’s only one problem, according to radio ...
(Date:5/6/2016)... ... 2016 , ... Canadian author Mark Black is a speaker, author, and life strategy ... the world … with the help of his publisher Strategic Book Group and its subsidiary ... a hospital bed waiting for a miracle: He needed a heart and double-lung transplant. From ...
(Date:5/6/2016)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has written a new article ... Bible about helping to stop cancer. Yisrayl says there are too many suffering and dying ... and science industries will pay close attention and take action. The Pastor says that the ...
Breaking Medicine News(10 mins):